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Should we screen for masked hypertension  
in patient with vascular disease?
Background: The influence of hypertension on cardiovascular risk is well known. Ambulatory 
blood pressure measurement (ABPM) is able to identify patients with masked hypertension 
(MH) underdetected by clinical BP measurement. The benefit of screening for MH in a high-
risk population was investigated.
Aims: To detect MH in a population with no prior history of hypertension and medically treated 
for peripheral or coronary arterial disease.
Methods: Thirty-eight consecutive patients with peripheral or coronary artery disease 
documented with arteriography, without a history of hypertension, and with an admission 
BP , 140/90 mmHg underwent ABPM after discharge. Ambulatory BP $ 125/80 mmHg 
were defined as MH.
Results: MH was found in 11 patients (28.9%). The MH group had a mean systolic and diastolic 
hospitalization BP significantly higher (127 versus 115 mmHg, respectively, P = 0.002 and 76 
versus 66 mmHg, P = 0.01), and tended to have a higher admission systolic BP and pulse pressure 
(127 versus 121 mmHg, respectively, P = 0.07; and 54 versus 46 mmHg, P = 0.06). The first 
BP measurement on the 24-hour ABPM was significantly higher in the MH group 140 versus 
121 mmHg, P = 0.001, for systolic BP and 84 versus 74 mmHg, P = 0.03, for diastolic BP.
Conclusions: MH was found in patients with documented and medically treated vascular 
disease. BP in the prehypertensive range is associated with MH. Systematic screening for MH 
in this high-risk population requires further investigation.
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Background
Arterial hypertension is a well documented risk factor in the cardiovascular disease 
continuum.1 Its diagnosis has traditionally relied on clinical blood pressure (BP) mea-
surement, but ambulatory BP monitoring (ABPM) offers a new method of identifying 
hypertensive disease and managing its consequences.
In addition to normotensive and “classically hypertensive” patients, it is now 
possible to distinguish between patients suffering from “white coat” hypertension 
and those with masked hypertension (MH). The definition of MH is BP values within 
normal limits on clinical examination which are increased during ABPM. Diagnosis of 
MH therefore relies on ABPM, which explains why a large portion of the population 
with MH is undiagnosed. MH has been recognized to have adverse consequences for 
patient prognosis in terms of cardiovascular morbidity, as well as target organ dam-
age. Its prevalence varies widely depending on sources or method of BP measurement 
(ABPM or self-measurement) but the outcome of MH is important in that it concerns 
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a large variety of patients, ranging from children to elderly 
patients, who are often already on treatment.2,3
Recent studies have shown that approximately 80% of 
patients suffering from vascular disease whether coronary, 
cerebral, or peripheral, have hypertension,4 and lowering of 
arterial BP favorably influences the prognosis, especially 
in patients with coronary lesions and those with a history 
of stroke.5,6
Recommendations for management of vascular patients 
emphasize the importance of testing and treatment for hyper-
tension.7 However, the methods that should be used to test 
for it have not been well outlined, and ABPM has not yet 
been included in the recommendations.
The use of ACE inhibition in patients with vascular 
disease has been validated by many studies showing its 
long term benefits for patient prognosis regardless of BP 
values,8,9 and prescription of ACE inhibitors has become 
routine in vascular patients, even in those not diagnosed 
with hypertension.
To date there are very little data available on MH, and 
it seems likely that mass screening will never be possible. 
However, it would be useful to determine risk factors which 
would raise suspicion of MH and thereby identify patients 
who would benefit from systematic testing. The purpose of 
this study was to confirm MH in patients with atherothrom-
botic vascular disease who are already on treatment, and to 
identify their risk factors.
Methods
Study population
We recruited patients from two wards of the Lille   University 
Hospital Center from September 2007 to July 2008. These 
patients were scheduled for coronary angiography or lower 
limb angiography. Inclusion criteria were systolic BP   
(SBP) , 140 mmHg, diastolic BP (DBP) , 90 mmHg, 
and at least one proven vascular atherothrombotic site 
(defined as a stenosis $ 50%). Forty-one patients gave 
verbal consent for ABPM testing. Due to false positive 
results on noninvasive ischemic testing, three patients 
were found to be free of atherothrombotic lesions and 
were therefore excluded. The 38 remaining patients were 
included in the study.
Arterial blood pressure measurement
Arterial BP was measured after at least 10 minutes of 
rest using a cuff adapted to patient size and a manual 
manometer. Mean BP and heart rate (HR) over the period 
of hospitalization was calculated using seven measurements 
for each patient collected by nurses using the electronic 
Datascope Acutor Plus device.
The participants underwent ABPM during usual   everyday 
activity a week later while still being treated, using a Spacelab 
Medical 90207 monitoring device, which recorded BP every 
15 minutes over a 24-hour period divided into daytime (from 
6 am to 10 pm) and nighttime (from 10 pm to 6 am).
Patients were then divided into two categories, ie, nor-
motensive patients with SBP and DBP at admission ,140 
and ,90 mmHg, respectively, as well as 24-hour ambula-
tory mean SBP , 125 mmHg and DBP , 80 mmHg, and 
MH patients with normal BP at admission but with 24-hour 
ambulatory mean SBP . 125 and DBP . 80 mmHg. 
This definition of MH is based on the European Society 
of Hypertension and European Society of Cardiology 
guidelines. This low BP level has already been used in a 
prospective, large-scale study using ABPM in patients who 
had never been previously treated with antihypertensive 
medication.10
The only antihypertensive drugs used in this patient 
  population with stable vascular disease were renin-
  angiotensin inhibitors. Patients with a prior history of myo-
cardial   infarction or left ventricular ejection fraction ,55% 
were excluded because they required beta-blockade therapy 
that could have influenced the study results.
Statistical analysis
SPSS software (SPSS, Chicago, IL) was used for statistical 
analysis. For the descriptive analysis, we extracted the median 
and frequency of each parameter for the two groups. The 
population of each group being under 30 patients, we chose 
a bivariate analysis with nonparametric testing. Quantitative 
testing relied on comparison of means using the Mann–
Whitney U test. Qualitative comparison of means was done 
using the Chi-squared test or Fisher’s exact test. Statistical 
significance was determined at P , 0.05.
Results
The prevalence of MH in our study population was 28.9% 
(Table 1). Of the 38 participants, 22 underwent lower 
limb angiography and the other 16 underwent coronary 
angiography. Four patients suffered from stable coronary 
disease diagnosed by coronary angiography during a previ-
ous hospitalization. No statistical differences between the 
masked hypertensive and normotensive groups were found 
for age, sex, or cardiovascular risk factors, nor were there 
any discernable differences in terms of treatment or biologic 
parameters.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Table 1 Population characteristics, and clinical and biologic data at hospital admission
Clinical and  biologic data Normotensive group  
(n = 27) 
Masked hypertensive group  
(n = 11)
P
Age (years, n) 55 ± 1.9 49 ± 2.8 0.43
Male gender (n) 24 9 0.45
Cardiovascular 
family history (n)
10 3 0.43
Coronary disease (n) 17 3 0.05
Peripheral artery disease (n) 6 3 0.28
COPD (n) 5 0 0.16
Current smoker (n) 18 7 0.57
Dyslipidemia (n) 17 3 0.05
Diabetes mellitus (n) 3 2 0.45
BMI (kg/m²) 26.3 ± 1.5 25 ± 0.9 0.38
Treatment before admission
  ACE inhibitor (n) 15
20
24
5
5
8
0.42
0.96
0.22
  Statin (n)
  Antiplatelet therapy (n)
Biologic data
  Creatinine (mg/L) 9 ± 0.3 9 ± 0.5 0.78
  GF Cockcroft (mL/min) 103.6 ± 6.9 94.1 ± 8.6 0.49
  GF MDRD (mL/min) 95.9 ± 4.2 88.7 ± 11.7 0.63
  HDL (g/L) 0.45 ± 0.02 0.46 ± 0.03 0.64
  LDL (g/L) 0.99 ± 0.08 1.12 ± 0.07 0.58
  Triglyceridemia (g/L) 1.18 ± 0.2 1.51 ± 0.4 0.29
Note: Values represent mean ± standard deviation. 
Abbreviations: COPD, chronic obstructive pulmonary disease; BMI, body mass index; ACE, angiotensin converting enzyme; GF, glomerular filtrate; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; MDRD, modification of diet in renal disease.
Table 2 Inhospital data
Inhospital  Normotensive 
group  
(n = 27)
Masked  
hypertensive  
group (n = 11)
P
Admission
  SBP (mmHg)
  DBP (mmHg)
  HR (beats per minute)
  PP (mmHg)
121 ± 1.9
73 ± 1.5
68 ± 2.8
47 ± 1.1
127.5 ± 2.7
78 ± 2.6
76.5 ± 4.1
51 ± 2.9
0.07
0.26
0.19
0.52
Inhospital stay
  Mean SBP (mmHg)
  Mean DBP (mmHg)
  Mean PP (mmHg)
115.8 ± 1.6
66.6 ± 1.0
46.7 ± 6.3
127.2 ± 1.3
76.1 ± 2.6
54.5 ± 5.9
0.002
0.01
0.06
Note: Values represents mean ± standard deviation.
Abbreviations: ACE, angiotensin converting enzyme inhibitors; BMI, body mass 
index; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; HR, heart rate; PP, pulse pressure. 
BP at admission versus ABPM
We noticed a difference, albeit not statistically significant, in 
BP between the two groups on admission (Table 2) and on 
ABPM (Table 3). MH patients seemed to have a higher mean 
SBP (P = 0.02) as well as a higher mean DBP (P = 0.01).
The first measurement carried out by the ABPM device 
in the presence of a nurse is considered a clinical BP mea-
surement and showed higher SBP (P = 0.01) and DBP 
(P = 0.03) in MH patients. We found the same significant 
difference while studying daytime SBP and DBP (P , 0.01 
and P = 0.009, respectively) as well as nighttime SBP and 
DBP (P = 0.001 and P = 0.03).
The same classes of antihypertensive treatment were 
utilized in both groups of patients during ABPM periods. 
SBP and DBP were once again found to be significantly 
higher in MH patients both during daytime (P , 0.001 
and P = 0.009, respectively) and nighttime measurements 
(P = 0.001 and P = 0.03).
Discussion
MH is not a well recognized illness, even though its unfavor-
able prognostic consequences for patients in terms of subse-
quent cardiovascular events has been largely   accepted.11 Its 
influence on intermediary markers of cardiovascular risk is 
well known and is much the same as that of   classical hyper-
tension. Kotsis et al demonstrated that patients suffering from 
MH had more severe target organ damage, with a larger left 
ventricular mass and thicker intima media than that found in 
a normotensive population.12 Ohasama observed a similarly 
unfavorable prognosis regarding cardiovascular morbidity 
and mortality in people with MH. The same study recorded a 
statistically higher risk of cardiovascular mortality and stroke 
in patients suffering from masked or regular hypertension 
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Table 3 Ambulatory 24-hour blood pressure monitoring data
Normotensive 
group (n = 27)
Masked hypertensive 
group (n = 11)
P
ABPM
  SBP, first measurement (mmHg)
  DBP, first measurement (mmHg)
24-hour ABPM
  SBP (mmHg)
  DBP (mmHg)
  HR (beats/min)
  PP (mmHg)
121 ± 3.3
74 ± 1.9
112 ± 1.6
67 ± 1.0
64 ± 2.1
46 ± 5.9
140 ± 3.1
84 ± 4.1
128.5 ± 1.3
78 ± 2.6
76 ± 4.5
51 ± 6.1
0.001
0.03
,0.001
0.02
0.12
0.002
ABPM during day
  SBP (mmHg)
  DBP (mmHg)
  HR (beats/min)
116 ± 1.7
72 ± 1.0
67 ± 2.1
133.5 ± 1.4
81.5 ± 2.8
75 ± 4.7
,0.001
0.009
0.17
ABPM during night
  SBP (mmHg)
  DBP (mmHg)
  HR (beats/min)
103 ± 22.4
61 ± 1.4
67 ± 2.3
120 ± 2.4
68 ± 2.5
75 ± 4.6
0.001
0.03
0.17
Treatment at discharge
  ACE inhibitors (n)
  Statin (n)
19
20
7
8
0.80
0.61
Values represent mean ± standard deviation.
Abbreviations: ABPM, ambulatory blood pressure monitoring; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; ACE, angiotensin-converting 
enzyme; PP, pulse pressure.
hypertension.13 This is equally true in populations of patients 
with treated   hypertension or untreated MH.14,15
When comparing MH patients with normotensive 
patients, we found a 15 mmHg gap between daytime and 
nighttime measurements for both SBP and DBP. This dif-
ference is important when considering the linear relationship 
between BP values and risk of cardiovascular events, and 
highlights the importance of considering the existence of MH 
when optimizing treatment in patients in need of secondary 
prevention.
Detection of MH during routine clinical examination is 
impossible and requires the use of ABPM, without which 
MH would probably be missed in patients requiring second-
ary prevention, thereby allowing undiagnosed and uncon-
trolled high blood pressure to increase their cardiovascular 
risk. Divergent data make it difficult to identify a specific 
kind of patient more likely to suffer from MH. However, 
Malion et al have suggested a profile of patients at high risk, 
ie, men who smoke and have higher triglyceride and lower 
HDL levels than the general normotensive population.16 Our 
study could not confirm this hypothesis, mainly because of 
the low number of patients recruited and the predominance 
of male subjects.
Our work confirmed the existence of MH in a predeter-
mined group of patients with no recorded history of hyper-
tension but undergoing treatment with   antihypertensive 
agents, prescribed principally for their antiatheromatous 
action. The existence of MH was indicated by higher BP, 
both during the hospitalization period and during measure-
ment before a consultation. This phenomenon has already 
been described, and indicates that the cut-off values for 
the diagnosis of hypertension at SBP 140 mmHg and DBP 
90 mmHg are inappropriate. This takes us in the same 
direction as the American guidelines for hypertension that 
define values for SBP of 130–139 mmHg and 80–89 mmHg 
for DBP as the prehypertensive range.17 Unfortunately, 
this definition seems to encompass too large a population 
according to data collected by the National Health and 
Nutrition Examination Survey (NHANES) that showed 
that 31% of all adults over the age of 20 had BP in the 
prehypertensive range.18
Diagnosing MH requires the use of ABPM, but mass 
testing using this method is impractical and should only be 
used in selected populations. Our work confirms other recent 
findings that patients with MH often have BP values in the 
upper normal range.19
The prognostic value of classifying hypertensive patients 
for primary and secondary prevention purposes is well-
known but the most effective diagnostic tools and the role of 
ABPM in this regard remain ill-defined. It seems reasonable 
to advocate that secondary prevention patients would benefit 
from ABPM because their BPs are at the upper limits of 
those considered to be normal according to recent European 
guidelines.20Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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The ideal solution would seem to be to determine 
other factors, whether clinical, anamnestic, or biologic, 
that could be used to calculate a score capable of predict-
ing a high probability of MH in the same way that the 
prevalent score is used to determine which patients would 
benefit from systolic index pressure measurement. Self-
measurement seems to be just as effective in detecting MH 
as ABPM but is more accessible, especially for general 
practitioners, and is more cost-effective. The optimal 
solution has yet to be defined and since ABPM has been 
the method of choice in a larger number of studies, it is 
more widely used.21
Our study shows a statistically significant difference bet-
ween nighttime and daytime SBP and DBP. Self-measurement 
appears to be a more limiting tool than ABPM, one major 
difference being that ABPM simplifies measurement of night-
time BP values at regular intervals. Nighttime hypertension is 
a risk factor for cardiovascular events and can be responsible 
for target organ damage. Nocturnal hypertension can be a sign 
of sleep apnea syndrome. Detection of nocturnal hypertension 
should prompt the physician to prescribe an evening antihy-
pertensive agent.
The main limitation of our study was its small sample 
size. Therefore it was not possible to assess frequency and 
outcomes of MH in a population of secondary prevention 
patients. However, patients with significant vascular disease, 
no prior history of hypertension, and free from any antihy-
pertensive treatment (except for renin-angiotensin system 
inhibitors) are not so frequent in current practice. We chose to 
exclude patients on antihypertensive treatment at admission 
in order to facilitate the interpretation of results. Finally, the 
definition of MH is debated; we chose in the present study to 
use the lower range of BP in accordance with recent published 
guidelines for management of systemic hypertension. As a 
consequence, the results of this study should be interpreted 
within these limitations.
Conclusion
MH is a separate entity with very real prognostic con-
sequences, as shown in studies comparing MH patients 
with normotensive patients. Its diagnosis in the setting 
of vascular disease appears to be necessary. Since mass 
testing is not practical, detection of MH should at the 
very least be   undertaken in specifically targeted high-risk 
populations.
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